Sells medicines for cancer, inflammatory conditions and other diseases to healthcare providers and pharmaceutical wholesalers.
10-K for FY2025, filed Feb 13, 2026
Amgen earns most of its revenue from selling medicines, with payment generally due after shipment. Other revenue comes mainly from royalties on licensed products and collaboration license fees, milestones and shares of commercial profits.
10-K for FY2025, filed Feb 13, 2026Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount…View ↗
Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and…View ↗
Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales…View ↗
$36.8B
10-K for FY2025, filed Feb 13, 2026
$36.8B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales
Sold outright
10-K for FY2025, filed Feb 13, 2026 |
96%
FY2022: 94%
|
Product sales, FY2025
$35.1B Sources
|
Sold outright |
|
Other revenues
|
4.4%
FY2022: 5.8%
|
Other revenues, FY2025
$1.6B Sources
|
In the United States, Amgen sells mainly to pharmaceutical wholesale distributors, which supply healthcare providers. Outside the United States, it sells mainly to healthcare providers or pharmaceutical wholesale distributors, based on local distribution practices; collaborators also help market medicines to providers.
10-K for FY2025, filed Feb 13, 2026The largest concentration of our sales and marketing forces is based in the United States and Europe. We also commercialize and market our…View ↗
In the United States, substantially all of our sales are to pharmaceutical wholesale distributors, which is the principal means of…View ↗
In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our…View ↗
10-K for FY2025, filed Feb 13, 2026
Years ended December 31, 2025 2024 2023 McKesson Corporation: Gross product sales $ 26,253 $ 22,173 $ 19,035 % of total gross revenues 34 %…View ↗
Yes. It kept 21 cents of every revenue dollar as net income in FY2025 and turned 22 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Jul 31, 2026
In July 2026, Amgen Inc. (the "Company") identified unauthorized activity involving data stored in cloud environments hosted by third-party…View ↗
8-K, filed May 19, 2026
On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive…View ↗
Growing. Revenue grew 41% in 4 years, from $26B in FY2021 to $36.8B in FY2025, about 9% a year.
More medicines for additional uses
The latest report describes expanded uses and approvals for marketed medicines, including UPLIZNA, TEZSPIRE, Repatha and IMDELLTRA. The older report focused on earlier trial results and approvals for products such as TEZSPIRE.
10-K for FY2022, filed Feb 9, 2023 10-K for FY2025, filed Feb 13, 2026In September 2022, the EC approved TEZSPIRE in the EU as an add-on therapy in patients 12 years and older with severe asthma who are…View ↗
In August 2025, we announced that the FDA broadened the approved use of Repatha to include adults at increased risk for major adverse…View ↗
In April 2025, we announced the FDA approved UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients.…View ↗
In December 2025, we announced the FDA approved UPLIZNA for the treatment of generalized myasthenia gravis (gMG) in adults who are…View ↗
In November 2025, we announced that the FDA granted full approval for IMDELLTRA for the treatment of adult patients with extensive stage…View ↗
In October 2025, we announced that the FDA approved TEZSPIRE as an add-on maintenance treatment of inadequately controlled chronic…View ↗
Wider product range
The latest report names a broader set of marketed products, including TEPEZZA, KRYSTEXXA, UPLIZNA and IMDELLTRA/IMDYLLTRA, alongside its principal products. The older report described a smaller set of selected marketed products.
10-K for FY2022, filed Feb 9, 2023 10-K for FY2025, filed Feb 13, 2026We market ENBREL, a tumor necrosis factor blocker, in the United States and Canada. ENBREL was launched in 1998 and is used primarily in…View ↗
We market Prolia in many countries around the world. Prolia contains the same active ingredient as XGEVA but is approved for different…View ↗
We market Otezla, a small molecule that inhibits phosphodiesterase 4 (PDE4), in many countries around the world. Otezla was acquired from…View ↗
We market XGEVA in many countries around the world. XGEVA was launched in 2010 and is used primarily in the indication for prevention of…View ↗
Competes with Regeneron Pharmaceuticals, Sanofi, Eli Lilly and, Bristol Myers Squibb, Pfizer, Asahi Kasei Pharma, AstraZeneca, GSK, Genentech, Celgene, Takeda Oncology, Legend Biotech, F. Hoffmann-La Roche, and Merck &
10-K for FY2025, filed Feb 13, 2026Regeneron Pharmaceuticals, Inc.View ↗
Loading...